The study is for Korean women who are postmenopausal and also suffer from osteoporosis.
The study will test if women who are given 20 mg of arzoxifene once a day for six months have a less severe level of osteoporosis than those women who do not take arzoxifene.
All patients will receive 500 mg of elemental calcium and 400 to 600 IU Vitamin D daily starting 4 weeks prior to study drug administration continuing through the 6 months of therapy.

Start Date01 Dec 2008

Sponsor / Collaborator

Eli Lilly & Co.

NCT00383422 / CompletedPhase 3

The Comparison of the Efficacy and Safety of Arzoxifene Versus Raloxifene in Postmenopausal Women With Osteoporosis

The purpose of this study is to compare the effect of arzoxifene to raloxifene on the bone mineral density (bone strength).

Start Date01 Oct 2006

Sponsor / Collaborator

Eli Lilly & Co.

EUCTR2006-001987-22-ES / Not yet recruitingPhase 3

Comparación de la Eficacia y Seguridad de Arzoxifeno frente a Raloxifeno en mujeres posmenopáusicas con Osteoporosis”The Comparison of the Efficacy and Safety of Arzoxifene versus Raloxifene in Postmenopausal Women with Osteoporosis - GJAR

Start Date28 Sep 2006

Sponsor / Collaborator-

100 Clinical Results associated with Arzoxifene Hydrochloride

100 Translational Medicine associated with Arzoxifene Hydrochloride

100 Patents (Medical) associated with Arzoxifene Hydrochloride

105

Literatures (Medical) associated with Arzoxifene Hydrochloride

19 Nov 2023·Cureus

Novel Advances in the Role of Selective Estrogen Receptor Modulators in Hormonal Replacement Therapy: A Paradigm Shift

Review

Author: Acharya, Neema ; Motlani, Vidhi ; Motlani, Gunjan ; Somyani, Drishti ; Agrawal, Shruti ; Dave, Apoorva ; Pamnani, Soumya

Estrogen is a key regulatory hormone in the functioning of a female reproductive system. Estrogen hormone regulates many complex physiological processes, which has its role in reproduction and skeletal and cardiovascular systems by acting on estrogen receptors alpha (ERα) and beta (ERβ), which are nuclear transcription factors. Selective estrogen receptor modulators (SERMs) are now being used to treat bone loss, breast carcinoma, and menopausal symptoms, metabolic neurodegenerative because of their characteristics that allow them to function as both estrogen agonists and antagonists, depending on the target tissue. First-generation SERMs, such as Tamoxifen, are used in the management protocol for breast cancer, which is estrogen receptor (ER-positive). Raloxifene is a second-generation SERM that is a valuable adjunct used to treat and prevent osteoporosis in postmenopausal women and prevent compression fractures of the vertebral column. Novel SERM molecules are on the horizon, proven more potent and efficacious in preventing and treating osteoporosis. These include Ospemifene, lasofoxifene, bazedoxifene and arzoxifene. The benefits of Raloxifene versus that of Bazedoxifene are under trial. Despite their therapeutic benefits and actions, these medications are not without adverse effects, such as thromboembolic disorders. Increased risk of uterine cancer has been linked to Tamoxifen. This article delves into the world of SERMs, including their development and discovery. The newer SERMs in late development, ospemifene, lasofoxifene, bazedoxifene, and arzoxifene, are described in detail.

01 Mar 2022·Archives of physical medicine and rehabilitationQ1 · MEDICINE

Reliability Validity and Responsiveness of the Spinal Cord Independence Measure 4th Version in a Multicultural Setup

Q1 · MEDICINE

Article

Author: Linda Sørensen ; Harvinder Singh Chhabra ; Luigi Tesio ; Amiram Catz ; Emiliana Bizzarini ; Dorothyann Curran ; Malka Itzkovich ; Ilaria Baroncini ; Mrinal Joshi ; Claudio Pilati ; Jean-Francois Lemay ; Ilana Gelernter ; Dianne Michaeli ; Einat Engel-Haber ; Thabata Pasquini Soeira ; Nan Liu ; Fin Biering-Sorensen ; Nur Kesiktas ; Aheed Osman ; Bobeena Chandy ; Vadim Bluvshtein ; Paulo Margalho ; Giulio Del Popolo ; Annelie Schedin Leiulfsrud ; Keren Elkayam ; Yoav Benjamini

OBJECTIVE:

To examine the fourth version of the Spinal Cord Independence Measure for reliability and validity.

DESIGN:

Partly blinded comparison with the criterion standard Spinal Cord Independence Measure III, and between examiners and examinations.

SETTING:

A multicultural cohort from 19 spinal cord injury units in 11 countries.

PARTICIPANTS:

A total of 648 patients with spinal cord injury.

INTERVENTION:

Assessment with Spinal Cord Independence Measure (SCIM IV) and Spinal Cord Independence Measure (SCIM III) on admission to inpatient rehabilitation and before discharge.

MAIN OUTCOME MEASURES:

SCIM IV interrater reliability, internal consistency, correlation with and difference from SCIM III, and responsiveness.

RESULTS:

Total agreement between examiners was above 80% on most SCIM IV tasks. All Kappa coefficients were above 0.70 and statistically significant (P<.001). Pearson's coefficients of the correlation between the examiners were above 0.90, and intraclass correlation coefficients were above 0.90. Cronbach's alpha was above 0.96 for the entire SCIM IV, above 0.66 for the subscales, and usually decreased when an item was eliminated. Reliability values were lower for the subscale of respiration and sphincter management, and on admission than at discharge. SCIM IV and SCIM III mean values were very close, and the coefficients of Pearson correlation between them were 0.91-0.96 (P<.001). The responsiveness of SCIM IV was not significantly different from that of SCIM III in most of the comparisons.

CONCLUSIONS:

The validity, reliability, and responsiveness of SCIM IV, which was adjusted to assess specific patient conditions or situations that SCIM III does not address, and which includes more accurate definitions of certain scoring criteria, are very good and quite similar to those of SCIM III. SCIM IV can be used for clinical and research trials, including international multi-center studies, and its group scores can be compared with those of SCIM III.

01 Mar 2021·Clinical rehabilitationQ2 · MEDICINE

An investigation into the validity and reliability of the Chinese version of Spinal Cord Independence Measure III (SCIM III)

Q2 · MEDICINE

Article

Author: Liu, Nan ; Xing, Huayi ; Biering-Sørensen, Fin

Objective::

To investigate the validity and reliability of a Chinese version of Spinal Cord Independence Measure III (SCIM III) in individuals with spinal cord injury.

Design::

Study on psychometric properties.

Setting::

An inpatient rehabilitation facility in China.

Subjects::

102 participants with spinal cord injury. Mean (SD) age was 48.8 (15.6) years; tetraplegia/paraplegia ratio was 50/52; median time post injury was 2 months.

Intervention::

SCIM III was translated into Chinese. Chinese versions of Barthel Index and SCIM III were filled out for each participant by Rater 1. SCIM III was then administered by Rater 2 after 24 hours ( n = 67) and 7 days ( n = 65).

Main Measures::

Validity, inter-rater/test-retest reliability, and internal consistency of the Chinese version of SCIM III.

Results::

The total scores between the two raters were similar (mean ± SD: 33.8 ± 25.8 vs 33.8 ± 25.5, P = 0.95). Total agreement between the raters in each item was >80%, with both Pearson and intraclass correlation coefficients >0.97 ( P < 0.01) for each subscale and total score. The Pearson correlation coefficients of the two independent assessments performed by Rater 2 were also >0.97 ( P < 0.01) for each subscale and the total score. Cronbach α was >0.7 for each subscale and the total score for both raters. High consistency was found between Barthel Index and SCIM III total scores (Pearson correlation coefficient = 0.88, P < 0.01).

Conclusion::

The Chinese version of SCIM III is valid and reliable for the functional assessment of patients with SCI.

News (Medical) associated with Arzoxifene Hydrochloride

14 Sep 2022

·www.biospace.com

Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable Complete Clinical Response in a Metastatic ER+/HER2- Breast Cancer Patient With an ESR1 Mutation After Prior CDK4/6 Inhibitor Treatment

Presentation delivered at the ninth-annual Metastatic Breast Cancer Research Conference in Park City, Utah Case was reported during Phase 2 study investigating efficacy of lasofoxifene, Sermonix’s lead investigational drug COLUMBUS, Ohio, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, broadly shared a case report detailing the first-ever known finding of a durable complete response that could be characterized as complete clinical remission in a metastatic estrogen receptor-positive (ER+)/HER2- breast cancer patient with an ESR1 mutation after prior CDK4/6 inhibitor treatment upon participation in any single-agent hormonally based therapy. The case report, “Durable Complete Remission of Metastatic ER+/HER2- Breast Cancer After Lasofoxifene Therapy,” was initially shared Sept. 9 at the ninth-annual Metastatic Breast Cancer Research Conference in Park City, Utah. Lasofoxifene is Sermonix’s lead investigational drug. The durable complete response (CR) was reported during Sermonix’s Phase 2 Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE 1, NCT03781063) study. The open-label, randomized study evaluated the efficacy of oral lasofoxifene versus intramuscular fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation and progression-free survival as the primary endpoint. Top-line ELAINE 1 data was presented Sept. 10 during the European Society for Medical Oncology (ESMO) Congress 2022 in Paris. Although not statistically significant, the results of the study numerically favored lasofoxifene. The patient was recruited to the ELAINE 1 study and started treatment on Dec. 16, 2020. Her first radiological assessment, eight weeks after lasofoxifene initiation via PET-FDG scan, revealed no pathological uptake in her pleural lesions, a sum diameter of 14 mm (55% reduction) and significant reduction of the bony lesion in the ilium with no new pathological findings. Scans at Week 16 revealed further improvement up to complete radiological disappearance of all measurable and non-measurable lesions. Radiological complete response was maintained at 80 weeks (June 29, 2022). “Achieving a complete response in metastatic breast cancer with endocrine treatment post CDK4/6 inhibitor is exceedingly uncommon, particularly with single-agent endocrine therapy,” said Dr. Einav Nili Gal-Yam, M.D., Ph.D., ELAINE 1 principal investigator and head of the Breast Oncology Institute at Chaim Sheba Medical Center in Ramat Gan, Israel. “This is a very gratifying result, pointing to lasofoxifene’s potentially significant role in addressing the unmet needs of patients with ESR1 mutations. We look forward to the continued clinical development of this drug.” About Lasofoxifene Lasofoxifene is an investigational, nonsteroidal selective estrogen receptor modulator (SERM), which Sermonix licensed globally from Ligand Pharmaceuticals Inc. (NASDAQ: LGND) and has been studied in previous comprehensive Phase 1-3 non-oncology clinical trials in more than 15,000 postmenopausal women worldwide. Lasofoxifene’s bioavailability and activity in mutations of the estrogen receptor could potentially hold promise for patients who have acquired endocrine resistance due to ESR1 mutations, a common finding in the metastatic setting and an area of high unmet medical need. Lasofoxifene’s novel activity in ESR1 mutations was discovered at Duke University and Sermonix has exclusive rights to develop and commercialize the product in this area. Lasofoxifene, a potent, oral SERM could, if approved, play a critical role in the targeted precision medicine treatment of advanced ER+ breast cancer. About Sermonix Sermonix Pharmaceuticals Inc. is a privately held biopharmaceutical company focused on the development of female-specific oncology products and is currently undertaking two Phase 2 clinical studies of lasofoxifene, its lead investigational drug. Sermonix Pharmaceuticals was founded in 2014 by David Portman, M.D., a leading clinical researcher and expert in women’s health, menopause and selective estrogen receptor modulator (SERM) therapy. The Sermonix management team, led by Dr. Portman, has significant experience in all stages of the drug development and regulatory process. Paul Plourde, M.D., vice president of oncology clinical development, has many decades of experience in the oncology drug development arena. Barry Komm, Ph.D., chief scientific officer, is recognized for his expertise in SERM biology. Miriam Portman, M.D., is chief operating officer. Elizabeth Attias, M.M.Sc., Sc.D., chief strategy and development officer, has extensive experience in pharmaceutical drug commercialization. Simon Jenkins, Ph.D., vice president of operations, has over 30 years of experience in global drug development leadership. Sermonix non-executive chairman of the board is Anthony Wild, Ph.D., former president of both Parke-Davis Pharmaceuticals and Warner-Lambert’s Pharmaceutical Division. Learn more at SermonixPharma.com. Contact information: Glenn Garmont LifeSci Advisors Managing Director, Investor Relations Corporate Communications ggarmont@lifesciadvisors.com 646-876-5521

Small molecular drug

13 Sep 2022

·www.biospace.com

Sermonix Pharmaceuticals Announces Results of Phase 2 Study of Lasofoxifene vs. Fulvestrant in Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation

COLUMBUS, Ohio, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced results of its signal-seeking Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE 1) Phase 2 study. The results were initially shared Sept. 10 during a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris. The open-label ELAINE 1 (NCT03781063) study began U.S. enrollment in September 2019, assessing the efficacy and safety of oral lasofoxifene versus intramuscular fulvestrant, a selective estrogen receptor degrader (SERD), in 103 patients. All participants were post-CDK4/6 inhibitor/aromatase inhibitor therapy and had an ESR1 mutation. Progression-free survival was the primary endpoint. Top-line data included: Median progression-free survival (PFS) was 6.04 mos. (95% CI, 2.82–8.04) for lasofoxifene vs. 4.04 mos. (95% CI, 2.93–6.04) for fulvestrant, P=0.138 (HR, 0.699 [95% CI, 0.445–1.125]) Clinical benefit rate (CBR) was 36.5% for lasofoxifene vs. 21.6% for fulvestrant, P=0.12. CBR is defined as the percentage of all subjects with a complete or partial response; or stable disease for >/= 24 weeks Objective response rate was 13.2% for lasofoxifene vs. 2.9% for fulvestrant, P=0.12, with 1 confirmed complete response (CR) (72-week duration) and 4 confirmed partial responses (PR) in the lasofoxifene arm vs. 1 PR in the fulvestrant arm PFS was numerically and consistently greater with lasofoxifene vs. fulvestrant when visceral metastasis and/or Y537S ESR1 mutation subgroups were analyzed While not reaching statistical significance in this 103-patient study, all endpoints numerically favored lasofoxifene Exploratory endpoints included: PFS at 6 mos. for lasofoxifene was 53.4% vs. 37.9% for fulvestrant; PFS at 12 mos. was 30.7% for lasofoxifene vs. 14.1% for fulvestrant Clearance of ctDNA also favored lasofoxifene over fulvestrant Most common adverse events were fatigue, nausea, arthralgias and hot flashes; most were Grade 1/2. No thrombotic events occurred ELAINE 1 is the first clinical trial comparing lasofoxifene with fulvestrant in ESR1-mutated metastatic breast cancer patients with progression on an aromatase inhibitor (Al) in combination with a CDK4/6 inhibitor, and the first to demonstrate anti-tumor activity and target engagement of a novel selective estrogen receptor modulator (SERM) in this setting. ELAINE 2, a Phase 2 single-arm trial of lasofoxifene in combination with the CDK4/6 inhibitor abemaciclib, showed efficacy in heavily pretreated patients with ESR1-mutated mBC post-CDK4/6i (ASCO 2022). “Sermonix is pleased with the outcomes reported in our ELAINE 1 trial comparing lasofoxifene with fulvestrant, suggesting lasofoxifene’s anti-tumor activity and potential to play a critical role in the targeted precision medicine treatment of ESR1-mutated advanced ER+ breast cancer,” said Dr. David Portman, Sermonix founder and chief executive officer. “Lasofoxifene following endocrine/CDK4/6 inhibitor therapies continues to be studied and we anticipate efficacy will be confirmed in a larger clinical study. Sermonix is planning a Phase 3 registrational combination study based on these results as well as encouraging efficacy and safety demonstrated in the ELAINE 2 study of lasofoxifene and abemaciclib reported at this year’s ASCO annual meeting.” “ELAINE 1 suggested lasofoxifene's activity in patients with metastatic breast cancer post-CDK4/6i and an ESR1 mutation,” said Dr. Paul Plourde, Sermonix vice president for clinical oncology development. “While not reaching statistical significance in our modestly powered study, all efficacy parameters numerically favored lasofoxifene over fulvestrant. Moreover, the safety pro lasofoxifene was well tolerated with few Grades 3 and 4 adverse events and a differentiated pro injectable and oral SERDs. Lasofoxifene trials may offer new hope for patients with mutated ESR1 metastatic breast cancer.” About Lasofoxifene Lasofoxifene is an investigational, nonsteroidal selective estrogen receptor modulator (SERM), which Sermonix licensed globally from Ligand Pharmaceuticals Inc. (NASDAQ: LGND) and has been studied in previous comprehensive Phase 1-3 non-oncology clinical trials in more than 15,000 postmenopausal women worldwide. Lasofoxifene’s bioavailability and activity in mutations of the estrogen receptor could potentially hold promise for patients who have acquired endocrine resistance due to ESR1 mutations, a common finding in the metastatic setting and an area of high unmet medical need. Lasofoxifene’s novel activity in ESR1 mutations was discovered at Duke University and Sermonix has exclusive rights to develop and commercialize the product in this area. Lasofoxifene, a potent, oral SERM could, if approved, play a critical role in the targeted precision medicine treatment of advanced ER+ breast cancer. About Sermonix Sermonix Pharmaceuticals Inc. is a privately held biopharmaceutical company focused on the development of female-specific oncology products and is currently undertaking two Phase 2 clinical studies of lasofoxifene, its lead investigational drug. Sermonix Pharmaceuticals was founded in 2014 by David Portman, M.D., a leading clinical researcher and expert in women’s health, menopause and selective estrogen receptor modulator (SERM) therapy. The Sermonix management team, led by Dr. Portman, has significant experience in all stages of the drug development and regulatory process. Paul Plourde, M.D., vice president of oncology clinical development, has many decades of experience in the oncology drug development arena. Barry Komm, Ph.D., chief scientific officer, is recognized for his expertise in SERM biology. Miriam Portman, M.D., is chief operating officer. Elizabeth Attias, M.M.Sc., Sc.D., chief strategy and development officer, has extensive experience in pharmaceutical drug commercialization. Simon Jenkins, Ph.D., vice president of operations, has over 30 years of experience in global drug development leadership. Sermonix non-executive chairman of the board is Anthony Wild, Ph.D., former president of both Parke-Davis Pharmaceuticals and Warner-Lambert’s Pharmaceutical Division. Learn more at SermonixPharma.com. Contact information: Glenn Garmont LifeSci Advisors Managing Director, Investor Relations Corporate Communications ggarmont@lifesciadvisors.com 646-876-5521

Small molecular drugASCO

25 Aug 2022

·www.biospace.com

Sermonix Pharmaceuticals Announces Top-Line Data From ELAINE 1 Phase 2 Study of Lasofoxifene Versus Fulvestrant Is Accepted for a Late-Breaking Oral Presentation at ESMO Congress 2022

COLUMBUS, Ohio, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced that top-line data from its Phase 2 study of lasofoxifene, its lead investigational drug, versus fulvestrant was accepted for a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress 2022, which is being held September 9-13, 2022, in Paris. The open-label, randomized Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE 1, NCT03781063) study, which began U.S. enrollment in September 2019, assessed the efficacy of oral lasofoxifene versus intramuscular fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic estrogen receptor-positive (ER+)/HER2- breast cancer with an ESR1 mutation and progression-free survival as the primary endpoint. Details of the presentation are as follows: Title: Open-label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors Presenter: Matthew P. Goetz Date, Time and Location: September 10 at 3:05 p.m. CEST, 7.2.E - Évry Auditorium Session: Mini Oral Session: breast cancer, metastatic Presentation Number: LBA20 About Lasofoxifene Lasofoxifene is an investigational, nonsteroidal selective estrogen receptor modulator (SERM), which Sermonix licensed globally from Ligand Pharmaceuticals Inc. (NASDAQ: LGND) and has been studied in previous comprehensive Phase 1-3 non-oncology clinical trials in more than 15,000 postmenopausal women worldwide. Lasofoxifene’s bioavailability and activity in mutations of the estrogen receptor could potentially hold promise for patients who have acquired endocrine resistance due to ESR1 mutations, a common finding in the metastatic setting and an area of high unmet medical need. Lasofoxifene’s novel activity in ESR1 mutations was discovered at Duke University and Sermonix has exclusive rights to develop and commercialize the product in this area. Lasofoxifene, a potent, oral SERM could, if approved, play a critical role in the targeted precision medicine treatment of advanced ER+ breast cancer. About Sermonix Sermonix Pharmaceuticals Inc. is a privately held biopharmaceutical company focused on the development of female-specific oncology products and is currently undertaking two Phase 2 clinical studies of lasofoxifene, its lead investigational drug. Sermonix Pharmaceuticals was founded in 2014 by David Portman, M.D., a leading clinical researcher and expert in women’s health, menopause and selective estrogen receptor modulator (SERM) therapy. The Sermonix management team, led by Dr. Portman, has significant experience in all stages of the drug development and regulatory process. Paul Plourde, M.D., vice president of oncology clinical development, has many decades of experience in the oncology drug development arena. Barry Komm, Ph.D., chief scientific officer, is recognized for his expertise in SERM biology. Miriam Portman, M.D., is chief operating officer. Elizabeth Attias, M.M.Sc., Sc.D., chief strategy and development officer, has extensive experience in pharmaceutical drug commercialization. Simon Jenkins, Ph.D., vice president of operations, has over 30 years of experience in global drug development leadership. Sermonix non-executive chairman of the board is Anthony Wild, Ph.D., former president of both Parke-Davis Pharmaceuticals and Warner-Lambert’s Pharmaceutical Division. Learn more at SermonixPharma.com. Contact information: Glenn Garmont LifeSci Advisors Managing Director, Investor Relations Corporate Communications ggarmont@lifesciadvisors.com 646-876-5521

Collaborate

100 Deals associated with Arzoxifene Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D02993	Arzoxifene Hydrochloride	-	DB06249

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Invasive Mammary Carcinoma	Phase 3	US	Eli Lilly & Co.	01 Jun 2004
Spinal Fractures	Phase 3	US	Eli Lilly & Co.	01 Jun 2004
Osteoporosis, Postmenopausal	Phase 3	US	Eli Lilly & Co.	01 Apr 2004
Locally advanced breast cancer	Phase 3	US	Eli Lilly & Co.	24 Apr 2002
Locally advanced breast cancer	Phase 3	AR	Eli Lilly & Co.	24 Apr 2002
Locally advanced breast cancer	Phase 3	CL	Eli Lilly & Co.	24 Apr 2002
Locally advanced breast cancer	Phase 3	IN	Eli Lilly & Co.	24 Apr 2002
Locally advanced breast cancer	Phase 3	MX	Eli Lilly & Co.	24 Apr 2002
Osteoporosis	Phase 2	KR	Eli Lilly & Co.	01 Dec 2008
Breast Cancer	Phase 2	US	National Cancer Institute	01 Aug 2000

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00005879 (CTgov)	Phase 2	Breast Cancer \| Hyperplasia	199	Placebo (Placebo)	nynypwfkgb(jtysfenlzo) = ijxqopydxf mzhvugqqor (ibcgksdvpj, gmnwpppbor - isejgzguft) View more	-	30 May 2017
				arzoxifene (Arzoxifene)	nynypwfkgb(jtysfenlzo) = bklcoogung mzhvugqqor (ibcgksdvpj, pwlljtzpsu - ibhwqqszzr) View more
NCT00088010 (Generations, Pubmed \| Breast Cancer Res)	Phase 3	Osteoporosis, Postmenopausal	9,369	Arzoxifene 20 mg/day	koquvzzmxj(ivtajszbyv) = there was a significant increase in some gynecological events with arzoxifene ggtovkzakb (rrvmrwbeok ) View more	Positive	01 Jul 2012
				Placebo
NCT00088010 (Pubmed \| J Bone Miner Res)	Phase 3	Fractures, Bone \| Invasive Mammary Carcinoma	9,369	Arzoxifene 20 mg	ygcemifitn(khgrghxoad) = pxcrbbkids swwicoylfk (hptitryeyc, 1.5 - 3.7)	-	01 Feb 2011
ASCO2006	Phase 2	Breast Diseases	199	Arzoxifene (LY353381.HCI, 20 mg daily)	pvfmtlxnme(cgnyfuxdaf) = cdjutbcsng ibenifryak (ltguphngfn )	-	20 Jun 2006
				Placebo	pvfmtlxnme(cgnyfuxdaf) = uxwyqogirj ibenifryak (ltguphngfn )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis